

Amy D Klion

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4782840/publications.pdf>

Version: 2024-02-01

189
papers

11,689
citations

31976

53
h-index

30922

102
g-index

193
all docs

193
docs citations

193
times ranked

10088
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study. <i>Gastroenterology</i> , 2022, 162, 1635-1649.	1.3	21
2	An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1217-1228.e3.	3.8	12
3	COVID-19 infection in hypereosinophilic syndrome: A survey-based analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	3.8	0
4	Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal Disease. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1598-1605.e2.	3.8	29
5	Comparison of Different Sampling Methods to Catch Lymphatic Filariasis Vectors in a Sudan Savannah Area of Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 1247-1253.	1.4	0
6	The Broad Spectrum of Eosinophilic Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1177.	3.8	0
7	Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2695-2709.	3.8	72
8	A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of <i>Loa loa</i> Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e1624-e1631.	5.8	10
9	Infection-associated Immune Perturbations Resolve 1 Year Following Treatment for <i>Loa loa</i> . <i>Clinical Infectious Diseases</i> , 2021, 72, 789-796.	5.8	8
10	Successful pregnancy in the setting of eosinophil depletion by benralizumab. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1405-1407.e3.	3.8	23
11	Remission of cold-agglutinin autoimmune hemolytic anemia and hypereosinophilic syndrome with rituximab therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2107-2108.e4.	3.8	0
12	Eosinophils and helminth infection: protective or pathogenic?. <i>Seminars in Immunopathology</i> , 2021, 43, 363-381.	6.1	19
13	Do rural health disparities affect prevalence data in pediatric eosinophilic esophagitis?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2549-2551.	3.8	5
14	Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	38
15	Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment. <i>Blood Reviews</i> , 2021, 49, 100809.	5.7	18
16	Feasibility of Onchocerciasis Elimination Using a “Test-and-not-treat” Strategy in <i>Loa loa</i> Co-endemic Areas. <i>Clinical Infectious Diseases</i> , 2021, 72, e1047-e1055.	5.8	6
17	A Test-and-Not-Treat Strategy for Onchocerciasis Elimination in <i>Loa loa</i> coendemic Areas: Cost Analysis of a Pilot in the Soa Health District, Cameroon. <i>Clinical Infectious Diseases</i> , 2020, 70, 1628-1635.	5.8	14
18	Loiasis. , 2020, , 859-863.		1

#	ARTICLE	IF	CITATIONS
19	Miscellaneous Filariae. , 2020, , 872-877.		2
20	Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 102-109.	9.1	34
21	Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 28-37.	2.9	17
22	Anti-CD30 Antibody for Eosinophilic Gastritis and Duodenitis. <i>New England Journal of Medicine</i> , 2020, 383, 1624-1634.	27.0	173
23	A new dawn for eosinophils in the tumour microenvironment. <i>Nature Reviews Cancer</i> , 2020, 20, 594-607.	28.4	164
24	Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migration. <i>Blood</i> , 2020, 136, 2667-2678.	1.4	23
25	Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1397-1405.	2.9	105
26	Single-Organ and Multisystem Hypereosinophilic Syndrome Patients with Gastrointestinal Manifestations Share Common Characteristics. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2718-2726.e2.	3.8	19
27	Symptom assessment in hypereosinophilic syndrome: Toward development of a patient-reported outcomes tool. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3209-3212.e8.	3.8	7
28	Platelet-derived growth factor receptor-alpha-positive myeloid neoplasm presenting as eosinophilic gastrointestinal disease. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2089-2091.	3.8	3
29	Contributions of Eosinophils to Human Health and Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 179-209.	22.4	144
30	Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features. <i>American Journal of Pathology</i> , 2020, 190, 1438-1448.	3.8	7
31	Advances in eosinophilic diseases in 2018. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1490-1494.	2.9	8
32	Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1598-1604.	2.9	7
33	Siglec-7 on peripheral blood eosinophils: Surface expression and function. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1257-1265.	5.7	21
34	Loa loa Microfilariae in Skin Snips: Consequences for Onchocerciasis Monitoring and Evaluation in L. loa-Endemic Areas. <i>Clinical Infectious Diseases</i> , 2019, 69, 1628-1630.	5.8	14
35	Benralizumab for <i>PDGFRA</i> -Negative Hypereosinophilic Syndrome. <i>New England Journal of Medicine</i> , 2019, 380, 1336-1346.	27.0	145
36	Eosinophilia. , 2019, , 519-526.		3

#	ARTICLE	IF	CITATIONS
37	Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. <i>Nucleic Acids Research</i> , 2019, 47, D1018-D1027.	14.5	539
38	Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2227-2237.e10.	2.9	50
39	Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD). <i>Journal of Leukocyte Biology</i> , 2018, 104, 69-83.	3.3	34
40	Swiss cheese heart. <i>European Heart Journal</i> , 2018, 39, 255-256.	2.2	0
41	Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 190-195.	3.8	48
42	Charcot-Leyden crystals: solving an enigma. <i>Blood</i> , 2018, 132, 2111-2112.	1.4	4
43	Soluble Siglec-8 Levels Are Detectable In Subjects With Myeloid Variant Hypereosinophilic Syndromes, But Not In Those With D816V KIT + Systemic Mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, AB277.	2.9	0
44	Hypereosinophilic syndrome: approach to treatment in the era of precision medicine. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 326-331.	2.5	33
45	Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1518-1527.e5.	3.8	64
46	Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. <i>Blood</i> , 2018, 132, 501-509.	1.4	52
47	Benralizumab (anti-IL5R α) depletes gut tissue eosinophilia and improves symptoms in hypereosinophilic syndrome with gastrointestinal involvement. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, AB196.	2.9	9
48	Glucocorticoid-induced eosinopenia in humans can be linked to early transcriptional events. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2076-2079.	5.7	16
49	Transcript- and protein-level analyses of the response of human eosinophils to glucocorticoids. <i>Scientific Data</i> , 2018, 5, 180275.	5.3	8
50	Factors Associated with <i>Wuchereria bancrofti</i> Microfilaremia in an Endemic Area of Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 1782-1787.	1.4	2
51	Immunophenotypic Patterns of Bone Marrow Eosinopoiesis in Patients with Hypereosinophilic Syndrome and Systemic Mastocytosis. <i>Blood</i> , 2018, 132, 4294-4294.	1.4	0
52	Dysregulation of interleukin 5 expression in familial eosinophilia. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1338-1345.	5.7	21
53	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. <i>New England Journal of Medicine</i> , 2017, 376, 1921-1932.	27.0	682
54	Surgical management of adult endocardial fibroelastosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, e81-e84.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. <i>Blood</i> , 2017, 129, 650-653.	1.4	74
56	Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection. <i>Clinical Infectious Diseases</i> , 2017, 64, 1017-1025.	5.8	24
57	Biologic Agents for the Treatment of Hypereosinophilic Syndromes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1502-1509.	3.8	35
58	A Test-and-Not-Treat Strategy for Onchocerciasis in "Endemic Areas. <i>New England Journal of Medicine</i> , 2017, 377, 2044-2052.	27.0	135
59	Clinical and Biological Markers in Hypereosinophilic Syndromes. <i>Frontiers in Medicine</i> , 2017, 4, 240.	2.6	29
60	Recent advances in understanding eosinophil biology. <i>F1000Research</i> , 2017, 6, 1084.	1.6	23
61	Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 803-810.	5.7	45
62	Hypereosinophilia in Children and Adults: A Retrospective Comparison. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 941-947.e1.	3.8	43
63	The long non-coding RNA Morrbid regulates Bim and short-lived myeloid cell lifespan. <i>Nature</i> , 2016, 537, 239-243.	27.8	234
64	Positivity of Antigen Tests Used for Diagnosis of Lymphatic Filariasis in Individuals Without <i>Wuchereria bancrofti</i> Infection But with High Loa loa Microfilaremia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1417-1423.	1.4	48
65	Dynamics of antigenemia and transmission intensity of <i>Wuchereria bancrofti</i> following cessation of mass drug administration in a formerly highly endemic region of Mali. <i>Parasites and Vectors</i> , 2016, 9, 628.	2.5	13
66	Siglec-7 on Peripheral Blood Eosinophils: Surface Expression and Functional Analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB167.	2.9	1
67	Dexpramipexole As a Steroid-Sparing Agent in Hypereosinophilic Syndromes (HES): An Open-Label Proof-of-Concept Study. <i>Blood</i> , 2016, 128, 1327-1327.	1.4	1
68	A Novel Therapeutic Target for the Treatment of Eosinophilic Disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB221.	2.9	0
69	Skin Histopathology in Patients with Dermatologic Manifestations of Hypereosinophilic Syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB266.	2.9	1
70	How I treat hypereosinophilic syndromes. <i>Blood</i> , 2015, 126, 1069-1077.	1.4	198
71	Eosinophilia: a pragmatic approach to diagnosis and treatment. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 92-97.	2.5	53
72	Novel Targeted Therapies for Eosinophil-Associated Diseases and Allergy. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 633-656.	9.4	47

#	ARTICLE	IF	CITATIONS
73	Preface. <i>Immunology and Allergy Clinics of North America</i> , 2015, 35, xi-xii.	1.9	1
74	Analysis of Nematode Motion Using an Improved Light-Scatter Based System. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003523.	3.0	8
75	Biologic Therapies Targeting Eosinophils: Current Status and Future Prospects. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 167-174.	3.8	88
76	Hypereosinophilic Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 304-305.	3.8	3
77	The Impact of Six Annual Rounds of Mass Drug Administration on <i>Wuchereria bancrofti</i> Infections in Humans and in Mosquitoes in Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 356-360.	1.4	19
78	Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder. <i>Haematologica</i> , 2015, 100, 300-307.	3.5	60
79	Eosinophil-Associated Processes Underlie Differences in Clinical Presentation of Loiasis Between Temporary Residents and Those Indigenous to Loa-Endemic Areas. <i>Clinical Infectious Diseases</i> , 2015, 60, 55-63.	5.8	41
80	Marked and persistent eosinophilia in the absence of clinical manifestations. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1195-1202.e2.	2.9	56
81	The eosinophil surface receptor epidermal growth factor- α -like module containing mucin-like hormone receptor 1 (EMR1): A novel therapeutic target for eosinophilic disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1439-1447.e8.	2.9	57
82	Highly heterogeneous, activated, and short-lived regulatory T cells during chronic filarial infection. <i>European Journal of Immunology</i> , 2014, 44, 2036-2047.	2.9	12
83	Eosinophils in vasculitis: characteristics and roles in pathogenesis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 474-483.	8.0	126
84	Predictors Of Response To Glucocorticoids In Hypereosinophilic Syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB76.	2.9	0
85	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 933.	2.9	0
86	Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1149-1161.	2.9	33
87	Differential Proteomic Analysis Of Eosinophils From Patients With Glucocorticoid Responsive Or Resistant Hypereosinophilic Syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB77.	2.9	0
88	Rapid development of migratory, linear, and serpiginous lesions in association with immunosuppression. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 1130-1134.	1.2	18
89	Development of a suspension array assay in multiplex for the simultaneous measurement of serum levels of four eosinophil granule proteins. <i>Journal of Immunological Methods</i> , 2014, 411, 11-22.	1.4	22
90	Eosinophilia and Eosinophil-Related Disorders. , 2014, , 1205-1223.		8

#	ARTICLE	IF	CITATIONS
91	The consequences of not having eosinophils. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 829-835.	5.7	108
92	<i>Wuchereria bancrofti</i> transmission pattern in southern Mali prior to and following the institution of mass drug administration. <i>Parasites and Vectors</i> , 2013, 6, 247.	2.5	18
93	Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 461-467.e5.	2.9	151
94	KIT GNNK splice variants: Expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells. <i>Experimental Hematology</i> , 2013, 41, 870-881.e2.	0.4	17
95	Loiasis. , 2013, , 823-826.		2
96	Diethylcarbamazine (DEC). , 2013, , 1098-1099.		0
97	Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome. <i>Blood</i> , 2013, 121, 2364-2366.	1.4	28
98	Eosinophilia. , 2013, , 501-509.		3
99	Miscellaneous Filariae. , 2013, , 835-839.		0
100	Filariasis Attenuates Anemia and Proinflammatory Responses Associated with Clinical Malaria: A Matched Prospective Study in Children and Young Adults. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1890.	3.0	51
101	Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus. <i>Journal of Experimental Medicine</i> , 2012, 209, 913-924.	8.5	59
102	Eosinophilia: Introduction. <i>Seminars in Hematology</i> , 2012, 49, 111-112.	3.4	0
103	Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 607-612.e9.	2.9	604
104	ICON: Eosinophil Disorders. <i>World Allergy Organization Journal</i> , 2012, 5, 174-181.	3.5	25
105	Therapeutic Approaches to Patients With Hypereosinophilic Syndromes. <i>Seminars in Hematology</i> , 2012, 49, 160-170.	3.4	27
106	Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 587-596.	2.9	54
107	Novel targeted therapies for eosinophilic disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 563-571.	2.9	90
108	Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: Review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8. <i>Journal of Immunological Methods</i> , 2012, 383, 39-46.	1.4	31

#	ARTICLE	IF	CITATIONS
109	Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Review of Hematology, 2012, 5, 157-176.	2.2	140
110	Interferon- γ -driven IL-12 and IFN- β in filarial-malaria coinfection. European Journal of Immunology, 2012, 42, 641-650.	2.9	28
111	Peripheral blood stem cell transplant-related <i>Plasmodium falciparum</i> infection in a patient with sickle cell disease. Transfusion, 2012, 52, 2677-2682.	1.6	23
112	Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1149-1156.	5.7	57
113	IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis. Journal of Allergy and Clinical Immunology, 2011, 128, 1086-1092.e3.	2.9	47
114	Loiasis and Mansonella Infections. , 2011, , 735-740.		11
115	Eosinophilic Myeloproliferative Disorders. Hematology American Society of Hematology Education Program, 2011, 2011, 257-263.	2.5	28
116	Filarial Infection Suppresses Malaria-Specific Multifunctional Th1 and Th17 Responses in Malaria and Filarial Coinfections. Journal of Immunology, 2011, 186, 4725-4733.	0.8	67
117	Use of High-Dose, Twice-Yearly Albendazole and Ivermectin to Suppress Wuchereria bancrofti Microfilarial Levels. Clinical Infectious Diseases, 2010, 51, 1229-1235.	5.8	33
118	Elevated Levels of Plasma Angiogenic Factors Are Associated with Human Lymphatic Filarial Infections. American Journal of Tropical Medicine and Hygiene, 2010, 83, 884-890.	1.4	30
119	Expanded Numbers of Circulating Myeloid Dendritic Cells in Patent Human Filarial Infection Reflect Lower CCR1 Expression. Journal of Immunology, 2010, 185, 6364-6372.	0.8	23
120	At Homeostasis Filarial Infections Have Expanded Adaptive T Regulatory but Not Classical Th2 Cells. Journal of Immunology, 2010, 184, 5375-5382.	0.8	101
121	Refining the definition of hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology, 2010, 126, 45-49.	2.9	273
122	Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology, 2010, 126, 828-835.e3.	2.9	95
123	Patent Filarial Infection Modulates Malaria-Specific Type 1 Cytokine Responses in an IL-10-Dependent Manner in a Filaria/Malaria-Coinfected Population. Journal of Immunology, 2009, 183, 916-924.	0.8	60
124	How I treat hypereosinophilic syndromes. Blood, 2009, 114, 3736-3741.	1.4	43
125	A Randomized Trial of Doxycycline for Mansonella perstans Infection. New England Journal of Medicine, 2009, 361, 1448-1458.	27.0	115
126	Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection. Pediatric Blood and Cancer, 2009, 53, 1120-1123.	1.5	32

#	ARTICLE	IF	CITATIONS
127	Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 1319-1325.e3.	2.9	502
128	Hypereosinophilic Syndrome: Current Approach to Diagnosis and Treatment. <i>Annual Review of Medicine</i> , 2009, 60, 293-306.	12.2	72
129	Filarial infections in travelers and immigrants. <i>Current Infectious Disease Reports</i> , 2008, 10, 50-57.	3.0	9
130	Molecular identification of Wolbachia from the filarial nematode <i>Mansonella perstans</i> . <i>Molecular and Biochemical Parasitology</i> , 2008, 160, 123-128.	1.1	57
131	Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab. <i>New England Journal of Medicine</i> , 2008, 358, 1215-1228.	27.0	536
132	Rapid, Novel, Specific, High-Throughput Assay for Diagnosis of <i>Loa loa</i> Infection. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2298-2304.	3.9	79
133	Transfusion-Associated Babesiosis with an Atypical Time Course after Nonmyeloablative Transplantation for Sickle Cell Disease. <i>Annals of Internal Medicine</i> , 2008, 148, 794.	3.9	18
134	Eosinophilia. , 2008, , 551-559.		0
135	Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFR α -positive chronic eosinophilic leukemia: implications for optimal dosing. <i>Blood</i> , 2007, 110, 3552-3556.	1.4	100
136	Approach to the Therapy of Hypereosinophilic Syndromes. <i>Immunology and Allergy Clinics of North America</i> , 2007, 27, 551-560.	1.9	14
137	KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFR α -associated chronic eosinophilic leukemia are distinct entities. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 680-687.	2.9	105
138	Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome. <i>American Journal of Hematology</i> , 2007, 82, 615-624.	4.1	20
139	Filariasis in Travelers Presenting to the GeoSentinel Surveillance Network. <i>PLoS Neglected Tropical Diseases</i> , 2007, 1, e88.	3.0	86
140	Year-to-Year Variation in the Age-Specific Incidence of Clinical Malaria in Two Potential Vaccine Testing Sites in Mali With Different Levels of Malaria Transmission Intensity. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 1028-1033.	1.4	31
141	Year-to-year variation in the age-specific incidence of clinical malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensity. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 1028-33.	1.4	25
142	Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1292-1302.	2.9	328
143	Platelet-derived growth factor receptor- β -associated hypereosinophilic syndrome and lymphomatoid papulosis. <i>British Journal of Dermatology</i> , 2006, 155, 824-826.	1.5	22
144	Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFR α -positive hypereosinophilic syndrome. <i>British Journal of Haematology</i> , 2006, 132, 286-292.	2.5	76

#	ARTICLE	IF	CITATIONS
145	CD2 identifies a monocyte subpopulation with immunoglobulin E-dependent, high-level expression of FcεRI. <i>Clinical and Experimental Allergy</i> , 2006, 36, 1436-1445.	2.9	34
146	Filaria-Induced Monocyte Dysfunction and Its Reversal following Treatment. <i>Infection and Immunity</i> , 2006, 74, 4409-4417.	2.2	55
147	Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease. <i>Journal of Clinical Investigation</i> , 2006, 116, 322-333.	8.2	122
148	Loiasis and Mansonella Infections. , 2006, , 1163-1175.		1
149	Systemic Mastocytosis with Eosinophilia: A Novel Diagnostic Approach To Distinguish Imatinib-Resistant Kit D816V-Associated Mast Cell Disease from Imatinib-Sensitive FIP1L1/PDGFRΑ-Associated Hypereosinophilic Syndrome.. <i>Blood</i> , 2006, 108, 2683-2683.	1.4	0
150	Safety and Tolerability of Anti-IL-5 Monoclonal Antibody (Mepolizumab) Therapy in Patients with HES: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.. <i>Blood</i> , 2006, 108, 2694-2694.	1.4	1
151	Recent Advances in the Diagnosis and Treatment of Hypereosinophilic Syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 209-214.	2.5	25
152	Imatinib-Responsive Hypereosinophilia in a Patient with B Cell ALL. <i>Leukemia and Lymphoma</i> , 2004, 45, 2497-2501.	1.3	21
153	Genetic heterogeneity in Loa loa parasites from southern Cameroon: A preliminary study. <i>Parasites and Vectors</i> , 2004, 3, 4.	1.3	7
154	Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. <i>Immunology and Allergy Clinics of North America</i> , 2004, 24, 645-666.	1.9	42
155	Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. <i>Seminars in Oncology</i> , 2004, 31, 12-17.	2.2	170
156	The role of eosinophils in host defense against helminth parasites. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 30-37.	2.9	385
157	Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1449-1455.	2.9	99
158	Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. <i>Blood</i> , 2004, 103, 2939-2941.	1.4	158
159	Familial eosinophilia: a benign disorder?. <i>Blood</i> , 2004, 103, 4050-4055.	1.4	71
160	Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. <i>Blood</i> , 2004, 103, 473-478.	1.4	237
161	The etiology of severe anemia in a village and a periurban area in Mali. <i>Blood</i> , 2004, 104, 1198-1200.	1.4	34
162	Lineage Analysis of the FIP1L1-PDGFRβ Fusion Gene in Myeloproliferative Hypereosinophilic Syndrome.. <i>Blood</i> , 2004, 104, 2441-2441.	1.4	9

#	ARTICLE	IF	CITATIONS
163	Familial Hypereosinophilic Syndrome. , 2004, , 189-194.		0
164	Serum Immunoglobulin G4 Antibodies to the Recombinant Antigen, L1, Are Highly Specific for Loa loa Infection. Journal of Infectious Diseases, 2003, 187, 128-133.	4.0	60
165	Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood, 2003, 101, 4660-4666.	1.4	359
166	Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?. Blood, 2003, 102, 3073-3074.	1.4	17
167	CLINICAL CHARACTERISTICS OF POST-TREATMENT REACTIONS TO IVERMECTIN/ALBENDAZOLE FOR WUCHERERIA BANCROFTI IN A REGION CO-ENDEMIC FOR MANSONELLA PERSTANS. American Journal of Tropical Medicine and Hygiene, 2003, 69, 331-335.	1.4	23
168	Clinical characteristics of post-treatment reactions to ivermectin/albendazole for Wuchereria bancrofti in a region co-endemic for Mansonella perstans. American Journal of Tropical Medicine and Hygiene, 2003, 69, 331-5.	1.4	14
169	The FAR proteins of filarial nematodes: secretion, glycosylation and lipid binding characteristics. Molecular and Biochemical Parasitology, 2002, 122, 161-170.	1.1	50
170	A high malaria reinfection rate in children and young adults living under a low entomological inoculation rate in a periurban area of Bamako, Mali.. American Journal of Tropical Medicine and Hygiene, 2002, 66, 310-313.	1.4	26
171	Pruritus and eosinophilia in a 14-year-old girl from Liberia. Journal of the American Academy of Dermatology, 2001, 45, 435-437.	1.2	6
172	Onchocerciasis in a Nonendemic Population: Clinical and Immunologic Assessment before Treatment and at the Time of Presumed Cure. Journal of Infectious Diseases, 2001, 183, 512-516.	4.0	34
173	Infectious diseases of international travel. Advances in Internal Medicine, 2001, 47, 265-92.	0.9	3
174	A novel developmentally regulated galectin of Onchocerca volvulus. Molecular and Biochemical Parasitology, 2000, 106, 187-195.	1.1	17
175	The relationship between serum IgE and surface levels of Fc̳R on human leukocytes in various diseases: Correlation of expression with Fc̳RI on basophils but not on monocytes or eosinophils. Journal of Allergy and Clinical Immunology, 2000, 106, 514-520.	2.9	113
176	Albendazole Therapy for Loiasis Refractory to Diethylcarbamazine Treatment. Clinical Infectious Diseases, 1999, 29, 680-682.	5.8	38
177	Lymphatic filariasis in a hyperendemic region: a ten-year, follow-up panel survey.. American Journal of Tropical Medicine and Hygiene, 1998, 59, 222-226.	1.4	12
178	Effectiveness of Diethylcarbamazine in Treating Loiasis Acquired by Expatriate Visitors to Endemic Regions: Long-Term Follow-Up. Journal of Infectious Diseases, 1994, 169, 604-610.	4.0	70
179	OvGalBP, a filarial antigen with homology to vertebrate galactoside-binding proteins. Molecular and Biochemical Parasitology, 1994, 65, 305-315.	1.1	56
180	Ceftazidime-related nonconvulsive status epilepticus. Archives of Internal Medicine, 1994, 154, 586-589.	3.8	3

#	ARTICLE	IF	CITATIONS
181	Ceftazidime-related nonconvulsive status epilepticus. Archives of Internal Medicine, 1994, 154, 586-9.	3.8	7
182	Albendazole in Human Loiasis: Results of a Double-Blind, Placebo-Controlled Trial. Journal of Infectious Diseases, 1993, 168, 202-206.	4.0	105
183	Pulmonary Involvement in Loiasis. The American Review of Respiratory Disease, 1992, 145, 961-963.	2.9	27
184	Cloning and characterization of a species-specific repetitive DNA sequence from Loa loa. Molecular and Biochemical Parasitology, 1991, 45, 297-305.	1.1	25
185	Loiasis in Endemic and Nonendemic Populations: Immunologically Mediated Differences in Clinical Presentation. Journal of Infectious Diseases, 1991, 163, 1318-1325.	4.0	158
186	AETIOLOGY OF OESOPHAGEAL CANCER. Lancet, The, 1987, 329, 1499-1500.	13.7	3
187	Defective gamma-interferon production in peripheral blood leukocytes of patients with acute tuberculosis. Journal of Clinical Immunology, 1986, 6, 146-151.	3.8	58
188	Regulation of IFN-gamma induction in human peripheral blood cells by exogenous and endogenously produced interleukin 2. Journal of Immunology, 1985, 135, 1851-6.	0.8	81
189	Diagnosis of Rare Eosinophilic and Mast Cell Disorders. , 0, , 825-837.		0